These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8385601)
1. Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia. Carrick JB; Morris DD; Moore JN Equine Vet J; 1993 Mar; 25(2):152-7. PubMed ID: 8385601 [TBL] [Abstract][Full Text] [Related]
2. Equine peritoneal macrophage production of thromboxane and prostacyclin in response to platelet activating factor and its receptor antagonist SRI 63-441. Morris DD; Moore JN Circ Shock; 1989 Jun; 28(2):149-58. PubMed ID: 2544315 [TBL] [Abstract][Full Text] [Related]
3. Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep. Christman BW; Lefferts PL; Blair IA; Snapper JR Am Rev Respir Dis; 1990 Dec; 142(6 Pt 1):1272-8. PubMed ID: 2174655 [TBL] [Abstract][Full Text] [Related]
4. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse. Foster AP; Lees P; Andrews MJ; Cunningham FM Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830 [TBL] [Abstract][Full Text] [Related]
6. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Handley DA; Van Valen RG; Melden MK; Flury S; Lee ML; Saunders RN Immunopharmacology; 1986 Aug; 12(1):11-6. PubMed ID: 3019921 [TBL] [Abstract][Full Text] [Related]
7. Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist. Lang CH; Dobrescu C; Hargrove DM; Bagby GJ; Spitzer JJ Circ Shock; 1987; 23(3):179-88. PubMed ID: 3427772 [TBL] [Abstract][Full Text] [Related]
8. The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction. Gans RO; DiPirro JC; Ueda Y; Niesen N; Lee KH; Brentjens JR J Lipid Mediat Cell Signal; 1994 Sep; 10(3):229-42. PubMed ID: 7812674 [TBL] [Abstract][Full Text] [Related]
9. Antagonism of endotoxin-induced disruption of equine gastrointestinal motility with the platelet-activating factor antagonist WEB 2086. King JN; Gerring EL J Vet Pharmacol Ther; 1990 Dec; 13(4):333-9. PubMed ID: 2287025 [TBL] [Abstract][Full Text] [Related]
10. Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Handley DA; Van Valen RG; Tomesch JC; Melden MK; Jaffe JM; Ballard FH; Saunders RN Immunopharmacology; 1987 Apr; 13(2):125-32. PubMed ID: 3597060 [TBL] [Abstract][Full Text] [Related]
11. Polymyxin B protects horses against induced endotoxaemia in vivo. Barton MH; Parviainen A; Norton N Equine Vet J; 2004 Jul; 36(5):397-401. PubMed ID: 15253079 [TBL] [Abstract][Full Text] [Related]
12. Effect of platelet-activating factor-receptor antagonism on endotoxin-induced lung dysfunction in sheep. Snapper JR; Lu W; Lefferts PL; Thabes JS J Appl Physiol (1985); 1998 May; 84(5):1610-4. PubMed ID: 9572806 [TBL] [Abstract][Full Text] [Related]
13. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Barton MH; Moore JN; Norton N Am J Vet Res; 1997 Nov; 58(11):1300-7. PubMed ID: 9361896 [TBL] [Abstract][Full Text] [Related]
14. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Kruse-Elliott KT; Albert DH; Summers JB; Carter GW; Zimmerman JJ; Grossman JE Shock; 1996 Apr; 5(4):265-73. PubMed ID: 8721386 [TBL] [Abstract][Full Text] [Related]
15. Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs. Olson NC; Joyce PB; Fleisher LN Am J Physiol; 1990 Jun; 258(6 Pt 2):H1674-86. PubMed ID: 2163217 [TBL] [Abstract][Full Text] [Related]
16. Effects of oral clenbuterol on the clinical and inflammatory response to endotoxaemia in the horse. Cudmore LA; Muurlink T; Whittem T; Bailey SR Res Vet Sci; 2013 Jun; 94(3):682-6. PubMed ID: 23462621 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the actions of platelet activating factor (PAF) antagonists WEB 2170 and WEB 2086 in the horse. Foster AP; Cunningham FM; Andrews MJ; Lees P J Vet Pharmacol Ther; 1993 Dec; 16(4):477-87. PubMed ID: 8126765 [TBL] [Abstract][Full Text] [Related]
19. Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia. László F; Whittle BJ; Moncada S Br J Pharmacol; 1994 Dec; 113(4):1131-6. PubMed ID: 7889265 [TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity of diabetic human platelets to platelet activating factor. Shukla SD; Paul A; Klachko DM Thromb Res; 1992 May; 66(2-3):239-46. PubMed ID: 1329254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]